Related Experiment Video

Updated: Mar 6, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.9K

Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver

Hong Bin Zhang1, Yan Yan1, Jin Peng Pang1

  • 1Interventional Radiology Department, Affiliated Fourth Hospital, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.

Oncotargets and Therapy
|March 5, 2026
PubMed

Insights

Metformin, a diabetes drug, shows promise in treating liver cancer by impacting key cellular processes. Research highlights its potential through the AMPK pathway for future clinical applications.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Liver cancer is a leading cause of cancer mortality globally.
  • Metformin, a common diabetes medication, exhibits potential anti-cancer properties.
  • The AMPK pathway is crucial in cellular processes relevant to cancer development.

Purpose of the Study:

  • To systematically review the mechanisms of metformin's action in liver cancer.
  • To explore the role of the AMPK pathway in metformin's anti-liver cancer effects.
  • To assess the potential clinical applications of metformin for liver cancer treatment.

Main Methods:

  • Literature review of relevant research studies.
  • Systematic exploration of metformin's molecular mechanisms.
  • Analysis of AMPK pathway involvement in metformin's anti-cancer effects.

Main Results:

  • Metformin influences autophagy, cell cycle arrest, angiogenesis, and epithelial-mesenchymal transition via the AMPK pathway.
  • Evidence suggests metformin's inhibitory effects on liver cancer cell proliferation.
  • The AMPK pathway is a key mediator of metformin's anti-tumor activity in liver cancer.

Conclusions:

  • Metformin demonstrates significant potential as a therapeutic agent for liver cancer.
  • The AMPK pathway is central to understanding metformin's efficacy in liver cancer.
  • Further research into metformin's mechanisms and clinical use in liver cancer is warranted.
Keywords:
AMPKautophagycell cycle arrestdrug synergyliver cancer

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.5K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
270